Adamas Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ADMS)

$33.77 -0.66 (-1.92 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$33.77
Today's Range$33.57 - $34.72
52-Week Range$13.50 - $44.00
VolumeN/A
Average Volume897,036 shs
Market Capitalization$868.44 million
P/E Ratio-10.05
Dividend YieldN/A
Beta1.17

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ADMS
CUSIPN/A
Phone+1-510-4503554

Debt

Debt-to-Equity Ratio0.41%
Current Ratio8.35%
Quick Ratio8.32%

Price-To-Earnings

Trailing P/E Ratio-10.0505952380952
Forward P/E Ratio-8.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$570,000.00
Price / Sales1,550.46
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book5.62

Profitability

Trailing EPS($3.36)
Net Income$-60,050,000.00
Net MarginsN/A
Return on Equity-68.00%
Return on Assets-53.83%

Miscellaneous

Employees69
Outstanding Shares26,170,000

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its earnings results on Thursday, November, 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.01) by $0.03. Adamas Pharmaceuticals's revenue for the quarter was down 99.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.66) earnings per share. View Adamas Pharmaceuticals' Earnings History.

Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2018?

8 analysts have issued 1 year price targets for Adamas Pharmaceuticals' shares. Their predictions range from $33.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $45.67 in the next twelve months. View Analyst Ratings for Adamas Pharmaceuticals.

What are Wall Street analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:

  • 1. Mizuho analysts commented, "We think the timing of the financing (in front of early Gocovri commercial updates) is ideal, and should allow shares to rebound quickly. There is an additional $12.75M greenshoe option that we expect to be filled as well. The company indicated it had $176.4M in cash/investments on its balance sheet as of December 31, 2017, up from $130.7M in cash at the end of 3Q:17, and also received a $65M payment from Healthcare Royalty Partners in 4Q:17. We estimate that Adamas therefore used ~$19.3M in cash in 4Q:17 and should have ~$270M in cash after the equity financing (with no additional financing needs this year). Because we believe that Adamas is a likely takeout target during a period of increased M&A activity and higher CNS valuations, it is possible that this could be its last financing event. We continue to view ADMS as our top pick in 2018, and reiterate our Buy rating." (1/23/2018)
  • 2. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (1/5/2018)

Who are some of Adamas Pharmaceuticals' key competitors?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:

  • Gregory T. Went Ph.D., Chairman of the Board, Chief Executive Officer, Co-Founder (Age 53)
  • Alfred G. Merriweather, Chief Financial Officer (Age 63)
  • Richard A. King, Chief Operating Officer (Age 52)
  • Leonie McConville, Senior Vice President - Human Resources (Age 53)
  • Christopher B. Prentiss, Principal Accounting Officer (Age 42)
  • Jennifer J. Rhodes, Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer (Age 47)
  • Martin Forrest, Vice President, Corporate Communications and Investor Relations
  • Rajiv Patni M.D., Chief Medical Officer (Age 48)
  • David L. Mahoney, Lead Independent Director (Age 62)
  • Mardi C. Dier, Director (Age 53)

Who owns Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.14%), Brenner West Capital Advisors LP (4.85%), Macquarie Group Ltd. (3.40%), Alliancebernstein L.P. (2.51%), Millennium Management LLC (2.51%) and Emerald Advisers Inc. PA (2.11%). Company insiders that own Adamas Pharmaceuticals stock include Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Natalie Mcclure, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Who sold Adamas Pharmaceuticals stock? Who is selling Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Kerrisdale Advisers LLC, Millennium Management LLC, Brenner West Capital Advisors LP, Cheyne Capital Management UK LLP, Granite Point Capital Management L.P., Mosaic Family Wealth LLC, TIAA CREF Investment Management LLC and BlackRock Inc.. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and William J Dawson. View Insider Buying and Selling for Adamas Pharmaceuticals.

Who bought Adamas Pharmaceuticals stock? Who is buying Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Driehaus Capital Management LLC, UBS Asset Management Americas Inc., Ardsley Advisory Partners, Macquarie Group Ltd., Deltec Asset Management LLC, Tamarack Advisers LP and Alliancebernstein L.P.. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy Adamas Pharmaceuticals stock?

Shares of Adamas Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of Adamas Pharmaceuticals stock can currently be purchased for approximately $33.77.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $868.44 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-60,050,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. Adamas Pharmaceuticals employs 69 workers across the globe.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 Powell St Ste 750, EMERYVILLE, CA 94608-2437, United States. The specialty pharmaceutical company can be reached via phone at +1-510-4503554 or via email at [email protected]


MarketBeat Community Rating for Adamas Pharmaceuticals (ADMS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adamas Pharmaceuticals (NASDAQ:ADMS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.67$45.67$42.00$35.50
Price Target Upside: 7.07% upside43.92% upside55.56% upside116.20% upside

Adamas Pharmaceuticals (NASDAQ:ADMS) Consensus Price Target History

Price Target History for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018MizuhoReiterated RatingBuy$48.00HighView Rating Details
12/19/2017Piper Jaffray CompaniesSet Price TargetBuy$52.00LowView Rating Details
12/13/2017CowenSet Price TargetBuy$55.00HighView Rating Details
11/29/2017Northland SecuritiesInitiated CoverageOutperform -> OutperformLowView Rating Details
11/8/2017Noble FinancialBoost Price TargetBuy$33.00 -> $48.00N/AView Rating Details
10/30/2017Evercore ISIInitiated CoverageOutperformN/AView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$38.00MediumView Rating Details
8/25/2017William BlairReiterated RatingOurperformHighView Rating Details
8/25/2017JMP SecuritiesReiterated RatingMkt Outperform -> Outperform$29.00 -> $33.00HighView Rating Details
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings History and Estimates Chart

Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ ADMS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($1.01)($1.04)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.93)$0.03 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.72)($0.72)$0.11 millionViewListenView Earnings Details
2/28/2017Q4($0.80)($0.68)$0.17 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.71)($0.78)$0.18 million$0.22 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)$0.18 millionViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)$0.10 million$0.52 millionViewN/AView Earnings Details
11/12/2015Q3($0.79)($0.81)$0.10 million$0.77 millionViewN/AView Earnings Details
8/11/2015Q215($0.67)($0.78)$0.10 million$0.40 millionViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)$0.10 million$0.23 millionViewN/AView Earnings Details
3/3/2015Q4 2014$0.64$0.50$30.18 million$30.30 millionViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)$0.18 million$0.22 millionViewN/AView Earnings Details
8/7/2014Q214$2.07$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.84 EPS
Next Year EPS Consensus Estimate: $-3.42 EPS

Dividends

Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 66.90%
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ ADMS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/21/2017Jennifer J. RhodesInsiderSell440$32.30$14,212.00View SEC Filing  
6/21/2017Great Point Partners LlcMajor ShareholderSell380,000$17.08$6,490,400.00View SEC Filing  
6/21/2017Jennifer J. RhodesInsiderSell1,041$17.53$18,248.73View SEC Filing  
6/19/2017Great Point Partners LlcMajor ShareholderSell350,000$17.05$5,967,500.00View SEC Filing  
3/21/2017Gregory T WentCEOSell2,807$17.03$47,803.21166,526View SEC Filing  
3/21/2017Rajiv PatniInsiderSell733$17.04$12,490.3213,642View SEC Filing  
3/21/2017William J DawsonCFOSell716$17.02$12,186.3214,284View SEC Filing  
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.0021,006View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.0048,000View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.0054,000View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.0057,000View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Adamas Pharmaceuticals (NASDAQ ADMS) News Headlines

Source:
DateHeadline
Adamas Pharma (ADMS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowAdamas Pharma (ADMS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:43 PM
Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018
finance.yahoo.com - February 14 at 6:37 AM
Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from BrokeragesAdamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 5:38 PM
Adamas Pharma (ADMS) Announces Publication of Amantadine Immediate Release Subgroup Analysis - StreetInsider.comAdamas Pharma (ADMS) Announces Publication of Amantadine Immediate Release Subgroup Analysis - StreetInsider.com
www.streetinsider.com - February 8 at 3:25 PM
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical PracticeAdamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
finance.yahoo.com - February 8 at 3:25 PM
Adamas to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceAdamas to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 6:28 AM
Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to "Hold"Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 3 at 2:32 PM
Adamas Pharma (ADMS) Reports Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal - StreetInsider.comAdamas Pharma (ADMS) Reports Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal - StreetInsider.com
www.streetinsider.com - February 2 at 6:28 AM
Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis JournalAdamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
finance.yahoo.com - February 2 at 6:28 AM
Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters Option to ... - GlobeNewswire (press release)Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters' Option to ... - GlobeNewswire (press release)
globenewswire.com - January 30 at 6:31 AM
Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional SharesAdamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 29 at 3:25 PM
Adamas Pharmaceuticals (ADMS) Upgraded to "Buy" at BidaskClubAdamas Pharmaceuticals (ADMS) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - January 28 at 10:34 AM
Adamas Pharma (ADMS) Prices 3M Shares at $41.50 - StreetInsider.comAdamas Pharma (ADMS) Prices 3M Shares at $41.50 - StreetInsider.com
www.streetinsider.com - January 24 at 3:28 PM
Adamas Pharmaceuticals (ADMS) Buy Rating Reiterated at MizuhoAdamas Pharmaceuticals' (ADMS) Buy Rating Reiterated at Mizuho
www.americanbankingnews.com - January 23 at 8:44 PM
Adamas Pharma (ADMS) Announces Proposed $85M Common Share OfferingAdamas Pharma (ADMS) Announces Proposed $85M Common Share Offering
www.streetinsider.com - January 23 at 11:52 AM
Adamas Announces Proposed Public Offering of Common StockAdamas Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 23 at 11:52 AM
Is Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Worth $38.19 Based On Its Intrinsic Value?Is Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Worth $38.19 Based On Its Intrinsic Value?
finance.yahoo.com - January 23 at 11:52 AM
After drug launch, growing East Bay company pays more for more space - San Francisco Business TimesAfter drug launch, growing East Bay company pays more for more space - San Francisco Business Times
www.bizjournals.com - January 21 at 8:16 AM
Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from AnalystsAdamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 19 at 7:36 PM
Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond - Seeking AlphaAdamas Pharmaceuticals: Continued Upside In 2018 And Beyond - Seeking Alpha
seekingalpha.com - January 16 at 3:41 PM
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up - NasdaqAdamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up - Nasdaq
www.nasdaq.com - January 12 at 3:40 PM
Adamas Pharmaceuticals Sees Unusually Large Options Volume (ADMS)Adamas Pharmaceuticals Sees Unusually Large Options Volume (ADMS)
www.americanbankingnews.com - January 12 at 2:38 AM
Nektar Notches New Highs As Stock Triples In Two MonthsNektar Notches New Highs As Stock Triples In Two Months
finance.yahoo.com - January 11 at 11:52 AM
4 Biotech/Pharma Stocks to Watch4 Biotech/Pharma Stocks to Watch
www.nasdaq.com - January 10 at 3:44 PM
After-Hours Movers 01/08: (ADMS) (SHLM) (STX) Higher; (BGFV) (ELF) (URBN) Lower (more...) - StreetInsider.comAfter-Hours Movers 01/08: (ADMS) (SHLM) (STX) Higher; (BGFV) (ELF) (URBN) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 9 at 3:44 PM
Adamas Pharma (ADMS) Announces US Commercial Launch of GOCOVRI for Treatment of Dyskinesia in PD - StreetInsider.comAdamas Pharma (ADMS) Announces US Commercial Launch of GOCOVRI for Treatment of Dyskinesia in PD - StreetInsider.com
www.streetinsider.com - January 9 at 3:44 PM
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication forAdamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for
www.nasdaq.com - January 9 at 11:06 AM
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease PatientsAdamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
finance.yahoo.com - January 9 at 11:06 AM
Adamas Pharmaceuticals (ADMS) Downgraded by Zacks Investment Research to "Hold"Adamas Pharmaceuticals (ADMS) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 5 at 4:52 PM
ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 27, 2017ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 12:42 PM
7 Stocks Ready to Jump Another 30% in 20187 Stocks Ready to Jump Another 30% in 2018
finance.yahoo.com - December 27 at 12:42 PM
Adamas Pharmaceuticals Inc (ADMS) Given Consensus Recommendation of "Buy" by AnalystsAdamas Pharmaceuticals Inc (ADMS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 25 at 5:57 PM
Adamas Pharmaceuticals Inc (ADMS) Insider Jennifer J. Rhodes Sells 440 SharesAdamas Pharmaceuticals Inc (ADMS) Insider Jennifer J. Rhodes Sells 440 Shares
www.americanbankingnews.com - December 21 at 5:52 PM
Piper Jaffray Companies Analysts Give Adamas Pharmaceuticals (ADMS) a $52.00 Price TargetPiper Jaffray Companies Analysts Give Adamas Pharmaceuticals (ADMS) a $52.00 Price Target
www.americanbankingnews.com - December 20 at 12:20 AM
Adamas Pharmaceuticals Inc (ADMS) Short Interest Down 11.3% in NovemberAdamas Pharmaceuticals Inc (ADMS) Short Interest Down 11.3% in November
www.americanbankingnews.com - December 18 at 4:36 PM
Adamas Pharmaceuticals (ADMS) Given a $55.00 Price Target at CowenAdamas Pharmaceuticals (ADMS) Given a $55.00 Price Target at Cowen
www.americanbankingnews.com - December 17 at 9:58 AM
ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 15, 2017ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 3:48 PM
Acorda Resubmits NDA for Parkinsons Disease Candidate InbrijaAcorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
www.zacks.com - December 8 at 3:42 PM
ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 4, 2017ETFs with exposure to Adamas Pharmaceuticals, Inc. : December 4, 2017
finance.yahoo.com - December 4 at 11:46 AM
Northland Securities Begins Coverage on Adamas Pharmaceuticals (ADMS)Northland Securities Begins Coverage on Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - November 29 at 8:44 AM
Can The Big Rally In Adamas Pharmaceuticals Continue? - Seeking AlphaCan The Big Rally In Adamas Pharmaceuticals Continue? - Seeking Alpha
seekingalpha.com - November 28 at 3:41 PM
ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 24, 2017ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 3:21 PM
Adamas to Present at Two Upcoming Investor Conferences - GlobeNewswire (press release)Adamas to Present at Two Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - November 22 at 4:05 PM
9 Stocks Steven Cohen Keeps Buying9 Stocks Steven Cohen Keeps Buying
finance.yahoo.com - November 22 at 4:05 PM
Adamas to Present at Two Upcoming Investor ConferencesAdamas to Present at Two Upcoming Investor Conferences
feeds.benzinga.com - November 22 at 1:39 PM
Contrasting Adamas Pharmaceuticals (ADMS) & Prosensa Holding NV (RNA)Contrasting Adamas Pharmaceuticals (ADMS) & Prosensa Holding NV (RNA)
www.americanbankingnews.com - November 14 at 7:44 PM
ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 13, 2017ETFs with exposure to Adamas Pharmaceuticals, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 6:10 PM
Adamas Pharmaceuticals (ADMS) and Its Peers Critical ContrastAdamas Pharmaceuticals (ADMS) and Its Peers Critical Contrast
www.americanbankingnews.com - November 11 at 10:16 AM
Adamas Announces New Employment Inducement Grant Nasdaq ... - GlobeNewswire (press release)Adamas Announces New Employment Inducement Grant Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - November 10 at 4:05 PM
Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Adamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 4:58 PM

SEC Filings

Adamas Pharmaceuticals (NASDAQ:ADMS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Adamas Pharmaceuticals (NASDAQ:ADMS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Adamas Pharmaceuticals (NASDAQ ADMS) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.